Literature DB >> 24429504

A study on druggability of MIA as a promising approach for inhibition of metastasis.

Jamal Shamsara1.   

Abstract

MIA (Melanoma Inhibitory Activity) protein is over expressed in melanoma cells and binds to extracellular matrix proteins as well as to several integrins. These interactions were suggested to promote formation of metastasis. Therefore, abrogation of MIA interaction with other proteins using small molecules might show a diminishing effect on cancer cell invasion. The present study is aimed at the analysis of the integrin-binding site of MIA using molecular docking, followed by a virtual screening for drug-like compounds that show potential as putative inhibitors of MIA-integrin interaction. Results showed that at the proposed binding interface of the MIA-integrin complex, a druggable binding pocket is located. Therefore, the integrin-binding domain of MIA was used as a receptor to screen 2200 drug-like compounds. Next, we analysed the interactions of the identified hit compounds with the MIA binding pocket to find the most important features of the hit compounds.

Entities:  

Year:  2014        PMID: 24429504     DOI: 10.1504/IJCBDD.2014.058594

Source DB:  PubMed          Journal:  Int J Comput Biol Drug Des        ISSN: 1756-0756


  3 in total

1.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

2.  Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma.

Authors:  King Tuo Yip; Xue Yin Zhong; Nadia Seibel; Stefanie Pütz; Jasmin Autzen; Raphael Gasper; Eckhard Hofmann; Jürgen Scherkenbeck; Raphael Stoll
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

3.  p-Hydroxylcinnamaldehyde induces the differentiation of oesophageal carcinoma cells via the cAMP-RhoA-MAPK signalling pathway.

Authors:  Ming Ma; Lian-Mei Zhao; Xing-Xiao Yang; Ya-Nan Shan; Wen-Xuan Cui; Liang Chen; Bao-En Shan
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.